Evidence map›Paper›PMID 37874461›Full record

ReviewJournal of endocrinological investigation2024

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.

M Schini, H Johansson, N C Harvey, M Lorentzon, J A Kanis, E V McCloskey

Abstract readReview
In one paragraph

Review in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Body mass index and subsequent fracture risk: a meta-analysis to update FRAX.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Pooled it
  3. Updated practice guideline for dual-energy X-ray absorptiometry (DXA).European journal of nuclear medicine and molecular imaging · 2025
    Guideline
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M SchiniDepartment of Oncology & Metabolism, Metabolic Bone Centre, Northern General Hospital, University of Sheffield, Herries Road, Sheffield, S5 7AU, UK. m.schini@sheffield.ac.uk.
H JohanssonSahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
N C HarveyMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
M LorentzonSahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
J A KanisMary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.ORCID http://orcid.org/0000-0002-3129-4326
E V McCloskeyDepartment of Oncology & Metabolism, Metabolic Bone Centre, Northern General Hospital, University of Sheffield, Herries Road, Sheffield, S5 7AU, UK.

Funding

Medical Research Council MC_PC_21003Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

FRAX®, a simple-to-use fracture risk calculator, was first released in 2008 and since then has been used increasingly worldwide. By calculating the 10-year probabilities of a major osteoporotic fracture and hip fracture, it assists clinicians when deciding whether further investigation, for example a bone mineral density measurement (BMD), and/or treatment is needed to prevent future fractures. In this review, we explore the literature around osteoporosis and how FRAX has changed its management. We present the characteristics of this tool and describe the use of thresholds (diagnostic and therapeutic). We also present arguments as to why screening with FRAX should be considered. FRAX has several limitations which are described in this review. This review coincides with the release of a version, FRAXplus, which addresses some of these limitations.

Indexed as

Hip FracturesOsteoporosisOsteoporotic FracturesBone DensityHumansRisk AssessmentCalculatorEpidemiologyFracture riskFracturesFRAXOsteoporosis

Identifiers

PMID37874461
PMCPMC10904566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.